Drug Firm Ikaria To Split In Two | Chemical & Engineering News
Volume 92 Issue 1 | p. 12 | Concentrates
Issue Date: January 6, 2014

Drug Firm Ikaria To Split In Two

Department: Business
Keywords: nitric oxide, respiratory failure, pharmaceuticals

The investor group that owns Ikaria will sell the company’s main business to Madison Dearborn Partners, a private equity firm, in a transaction it values at $1.6 billion. Ikaria markets nitric oxide as a treatment for respiratory failure in infants. The discovery of nitric oxide’s role as a signaling molecule in the cardiovascular system won the 1998 Nobel Prize in Medicine. Ikaria’s owners will retain the firm’s research operation, which will start with $80 million to develop nitric oxide for other applications.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment